drugset / Trial / NCT01965158

Efficacy and Safety of Naldemedine in the Treatment of Opioid-induced Constipation

NCT01965158

Phase 3 Completed 547 enrolled Shionogi
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of naldemedine in the treatment of opioid-induced constipation (OIC) in adults with non-malignant chronic pain who are not using laxatives.

Timeline

Start
2013-08-29
Primary completion
2015-01-22
Completion
2015-01-22

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Naldemedine Other / unclassified 0.2 mg Oral